Cerebral Venous Sinus Thrombosis Clinical Trial
Official title:
Safety and Efficacy of the Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus Thrombosis.
NCT number | NCT05291585 |
Other study ID # | CVST-EVT |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2021 |
Est. completion date | December 2022 |
A prospective, single-center, open-label,randomized, controlled,non-inferiority clinical trial will be conducted to evaluate the safety and efficacy of a dedicated venous sinus thrombectomy stent for endovascular treatment of cerebral venous sinus thrombosis.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2022 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Cerebral venous sinus thrombosis (from onset to randomization less than 28 days) confirmed by cerebral angiography, magnetic resonance venography or computed tomographic venography 2. Severe form of CVT with a high chance of incomplete recovery, as defined by the presence of one or more of the following risk factors 1. Clinical deterioration or progression despite anticoagulation 2. Stupor, Coma (Glasgow coma scale < 9) or mental status disorder 3. Involvement of multiple sinus veins results in severe high cranial pressure and rapid vision loss 4. Venous infarction or intracranial hemorrhage with high load venous sinus thrombosis 5. Thrombosis of the straight sinus 3. The subject (or his/her guardian) agrees to participate in this study and signs the informed consent Exclusion Criteria: Age less than 18 years Duration from onset to randomization more than 28 days Recurrent CVST Pregnancy (women in the puerperium may be included) Isolated cavernous sinus thrombosis or isolated cortical vein thrombosis Clinical and radiological signs of impending transtentorial herniation due to large space-occupying lesions and 4th ventricle compression and hydrocephalus, which requires emergency surgery Recent (< 2 weeks) major surgical procedure (does not include lumbar puncture) or severe cranial trauma Contraindication for anti-coagulant or thrombolytic treatment 1. documented generalized bleeding disorder 2. concurrent thrombocytopenia (<100 x 10E9/L) 3. severe hepatic or renal dysfunction, that interferes with normal coagulation 4. gastrointestinal tract hemorrhage (< 3 months, not including hemorrhage from rectal hemorrhoids) Any known serious condition (such as terminal cancer) with a poor short term (1 year) prognosis independent Known allergy against contrast used during endovascular procedures or the thrombolytic or anticoagulation drug used Previously legally incompetent prior to CVST No informed consent Other conditions judged by the researcher to be unsuitable for inclusion. |
Country | Name | City | State |
---|---|---|---|
China | Xuan Wu Hospital,Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Ji Xunming,MD,PhD |
China,
Coutinho JM, Zuurbier SM, Bousser MG, Ji X, Canhão P, Roos YB, Crassard I, Nunes AP, Uyttenboogaart M, Chen J, Emmer BJ, Roosendaal SD, Houdart E, Reekers JA, van den Berg R, de Haan RJ, Majoie CB, Ferro JM, Stam J; TO-ACT investigators. Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis: The TO-ACT Randomized Clinical Trial. JAMA Neurol. 2020 Aug 1;77(8):966-973. doi: 10.1001/jamaneurol.2020.1022. — View Citation
Fan Y, Yu J, Chen H, Zhang J, Duan J, Mo D, Zhu W, Wang B, Ouyang F, Chen Y, Lan L, Zeng J; Chinese Stroke Association Stroke Council CVST Guideline Writing Committee. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis. Stroke Vasc Neurol. 2020 Jun;5(2):152-158. doi: 10.1136/svn-2020-000358. Epub 2020 May 13. Review. — View Citation
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004 Mar;35(3):664-70. Epub 2004 Feb 19. — View Citation
Goyal M, Fladt J, Coutinho JM, McDonough R, Ospel J. Endovascular treatment for cerebral venous thrombosis: current status, challenges, and opportunities. J Neurointerv Surg. 2022 Jan 12. pii: neurintsurg-2021-018101. doi: 10.1136/neurintsurg-2021-018101. [Epub ahead of print] Review. — View Citation
Lee SK, Mokin M, Hetts SW, Fifi JT, Bousser MG, Fraser JF; Society of NeuroInterventional Surgery. Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee. J Neurointerv Surg. 2018 Aug;10(8):803-810. doi: 10.1136/neurintsurg-2018-013973. Epub 2018 Jun 5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | CVST pathological markers | CVST pathological markers of blood, clot and cerebral spinal fluid(CRP,IL-6,NSE,NLR,etc. | pre-procedure, intra-operative, up to 7 days | |
Other | Imaging database | neuroimaging: MRV/CTV | pre-procedure and 90 days post-procedure | |
Primary | Success rate of immediate recanalization | 3-grade classification scheme that considers different grades for patients with complete recanalization, partial recanalization and no recanalization.
Complete recanalization defined as blood flow without any interruption, Partial recanalization defined as small interruptions of continuous blood flow and narrowing of the venous lumen No recanalization defined as interrupted blood flow. |
immediately intra-operative | |
Secondary | The proportion of functional independence (modified Rankin score 0-2) | 0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead. | up to 7 days and 90 days post-procedure | |
Secondary | The time of thrombectomy procedure | The time of thrombectomy procedure refers to the time from entry of thrombectomy device to vascular recanalization) or the end time of surgery for patients with no vascular recanalization | intra-operative | |
Secondary | Changes in NIHSS score | Changes in NIHSS score 7days or at discharge and 90 days post-procedure compared with pre-procedure. | pre-procedure, up to 7 days and 90 days post-procedure | |
Secondary | Success rate of instrument operation | Device operation success = the number of devices completed conveying to the occlusive segment of the sinus, releasing and retracting in the group/the number of all test devices used in the group ×100% | intra-operative | |
Secondary | The proportion of symptom-free and improved | The symptoms include headache, visual dysfunction, tinnitus, cognitive disorder and epilepsy, etc. | up to 7 days and 90 days post-procedure | |
Secondary | CSF opening pressure | Change of CSF opening pressure 7 days or at discharge post-procedure compared with pre-procedure by lumbar puncture | up to 7days | |
Secondary | Modified Rankin Scale | Distribution of Modified Rankin Scale | up to 7 days and 90 days post-procedure | |
Secondary | The incidence of symptomatic intracranial hemorrhage | Symptomatic intracranial hemorrhage within 7 days post-procedure, specifically intracranial hemorrhage (intracranial parenchymal hematoma, subarachnoid hemorrhage, an ventricular hemorrhage) accompanied by neurological deterioration (NIHSS score increased by =4 points compared with pre-procedure. | within 7 days post-procedure | |
Secondary | Peri-procedural complications | Procedure associated complications: vasospasm, dissection, perforation and emboli to new territory. | intra-operative and 7 days post-procedure | |
Secondary | All cause mortality | All cause mortality within 90 days post-procedure | within 90 days post-procedure | |
Secondary | Incidence of device defects | Defects of research devices during clinical trials, such as operational difficulties, broken devices and any incident related with device defects. | intra-operative | |
Secondary | Incidence of SAE (serious adverse events) or AE (adverse events) | Incidence of SAE (serious adverse events) or AE (adverse events) intra-operative, 24 hours, 7 days and 90 days post-procedure | intra-operative, 24 hours, 7 days and 90 days post-procedure | |
Secondary | The recurrence rate of CVST | The recurrence rate of CVST confirmed by clinical manifestations and imaging examinations | up to 7 days and 90 days post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04269954 -
The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis
|
Phase 4 | |
Not yet recruiting |
NCT03919305 -
Cerebral Venous Thrombosis Cohort Study in China Mainland
|
||
Recruiting |
NCT03273179 -
Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales
|
N/A | |
Recruiting |
NCT04966182 -
Application CT and MRI in Cerebral Venous Sinus Thrombosis
|
||
Recruiting |
NCT05021198 -
The Norwegian Cerebral Venous Thrombosis Study
|
||
Withdrawn |
NCT04580238 -
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
|
Phase 1 | |
Completed |
NCT05448248 -
Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
|